Relations of lipid concentrations to heart failure incidence the framingham heart study

Circulation

Volumn 120, Issue 23, 2009, Pages 2345-2351

  Velagaleti, Raghava S ^a   Massaro, Joseph ^a,b   Vasan, Ramachandran S ^a,c   Robins, Sander J ^a   Kannel, William B ^a   Levy, Daniel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology; Heart failure; Hypercholesterolemia; Lipids; Risk factors

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

ADULT; ARTICLE; ATTRIBUTABLE RISK; CARDIOVASCULAR RISK; CLINICAL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ADULT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INCIDENCE; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 73449104555     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.830984     Document Type: Article

References (47)

1. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB, Hong Y. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117:2544-2565.
2. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
3. Martin JH, Krum H. Statins and clinical outcomes in heart failure. Clin Sci (Lond). 2007;113:119-127. (Pubitemid 47237908)
4. Eriksson H, Svardsudd K, Larsson B, Ohlson LO, Tibblin G, Welin L, Wilhelmsen L. Risk factors for heart failure in the general population: the study of men born in 1913. Eur Heart J. 1989;10:647-656.
5. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994;72:S3-S9.
6. Palmiero P, Maiello M, Passantino A, Antoncecchi E, Deveredicis C, DeFinis A, Ostuni V, Romano E, Mengoli P, Caira D. Correlation between diastolic impairment and lipid metabolism in mild-to-moderate hypertensive postmenopausal women. Am J Hypertens. 2002;15:615-620.
7. Rietzschel ER, Langlois M, De Buyzere ML, Segers P, De Bacquer D, Bekaert S, Cooman L, Van Oostveldt P, Verdonck P, De Backer GG, Gillebert TC. Oxidized low-density lipoprotein cholesterol is associated with decreases in cardiac function independent of vascular alterations. Hypertension. 2008;52:535-541.
8. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41:279-281.
9. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham Study. Ann N Y Acad Sci. 1963;107:539-556.
10. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110:281-290.
11. Wilson PW, Hoeg JM, D'Agostino RB, Silbershatz H, Belanger AM, Poehlmann H, O'Leary D, Wolf PA. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med. 1997;337:516-522.
12. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta. 1987;166:1-8.
13. Albers JJ, Warnick GR, Wiebe D, King P, Steiner P, Smith L, Breck-enridge C, Chow A, Kuba K, Weidman S, Arnett H, Wood P, Shlagenhaft A. Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin Chem. 1978;24:853-856.
14. Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol. 1998;81:26B-31B.
15. Kannel WB, Wolf PA, Garrison RJ, eds. Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death in Pooled Repeated Biennial Measurements: Section 34: The Framingham Heart Study: 30 Year Follow-Up. Bethesda, Md: National Institutes of Health; 1987. NIH publication 87-2703.
16. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-1446.
17. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2002. Available at: http://www.nhlbi.ni-h. gov/guidelines/cholesterol/atp3-rpt.htm. Accessed November 9, 2009.
18. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. The Lipid Research Clinics Program Epidemiology Committee. Circulation. 1979;60:427-439.
19. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statistics\-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
20. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myo-cardial infarction: an update on the Framingham Study. N Engl J Med. 1984;311:1144-1147.
21. Sheifer SE, Manolio TA, Gersh BJ. Unrecognized myocardial infarction. Ann Intern Med. 2001;135:801-811.
22. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age: a report based on the Framingham data. Arch Intern Med. 1993;153:1065-1073.
23. Skwarek M, Bilinska ZT, Mazurkiewicz L, Grzybowski J, Kruk M, Kurjata P, Piotrowski W, Ruzyllo W. Significance of dyslipidaemia in patients with heart failure of unexplained aetiology. Kardiol Pol. 2008; 66:515-522.
24. Ingelsson E, Arnlov J, Sundstrom J, Zethelius B, Vessby B, Lind L. Novel metabolic risk factors for heart failure. J Am Coll Cardiol. 2005; 46:2054-2060.
25. Djousse L, Gaziano JM. Egg consumption and risk of heart failure in the Physicians' Health Study. Circulation. 2008;117:512-516.
26. Yamagishi K, Nettleton JA, Folsom AR. Plasma fatty acid composition and incident heart failure in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008;156:965-974.
27. Ingelsson E, Arnlov J, Lind L, Sundstrom J. Metabolic syndrome and risk for heart failure in middle-aged men. Heart. 2006;92:1409-1413.
28. Dhingra R, Sesso HD, Kenchaiah S, Gaziano JM. Differential effects of lipids on the risk of heart failure and coronary heart disease: the Physicians' Health Study. Am Heart J. 2008;155:869-875.
29. Celentano A, Crivaro M, Roman MJ, Pietropaolo I, Greco R, Pauciullo P, Lirato C, Devereux RB, de Simone G. Left ventricular geometry and arterial function in hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2001;11:312-319. (Pubitemid 33687820)
30. Schiffrin EL. Vascular stiffening and arterial compliance: implications for systolic blood pressure. Am J Hypertens. 2004;17:39S-48S.
31. Jullien V, Gosse P, Ansoborlo P, Lemetayer P, Clementy J. Relationship between left ventricular mass and serum cholesterol level in the untreated hypertensive. J Hypertens. 1998;16:1043-1047. (Pubitemid 28367960)
32. Huang Y, Walker KE, Hanley F, Narula J, Houser SR, Tulenko TN. Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation. 2004;109:97-102.
33. Maczewski M, Maczewska J. Hypercholesterolemia exacerbates ventricular remodeling in the rat model of myocardial infarction. J Card Fail. 2006;12:399-405.
34. Rodriguez-Porcel M, Lerman A, Best PJ, Krier JD, Napoli C, Lerman LO. Hypercholesterolemia impairs myocardial perfusion and permeability: role of oxidative stress and endogenous scavenging activity. J Am Coll Cardiol. 2001;37:608-615.
35. Schillaci G, Vaudo G, Reboldi G, Verdecchia P, Lupattelli G, Pasqualini L, Porcellati C, Mannarino E. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens. 2001; 19:2265-2270. (Pubitemid 33135250)
36. Horio T, Miyazato J, Kamide K, Takiuchi S, Kawano Y. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens. 2003;16: 938-944.
37. Wang TD, Lee CM, Wu CC, Lee TM, Chen WJ, Chen MF, Liau CS, Sung FC, Lee YT. The effects of dyslipidemia on left ventricular systolic function in patients with stable angina pectoris. Atherosclerosis. 1999; 146:117-124.
38. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Polonski L, Dyrbus K, Badzinski A, Mercik G, Zembala M, Wodniecki J, Rozek MM. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol. 2006;97:899-904.
39. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation. 2001;104:2376-2383. (Pubitemid 33049524)
40. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB. Inflammatory markers and risk of heart failure in elderly subjects without prior myo-cardial infarction: the Framingham Heart Study. Circulation. 2003;107: 1486-1491. (Pubitemid 36378485)
41. Cockerill GW, Huehns TY, Weerasinghe A, Stocker C, Lerch PG, Miller NE, Haskard DO. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 2001;103:108-112.
42. Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol. 2002;13:285-288.
43. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Luscher TF, Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105:1399-1402.
44. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
45. Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ. High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arterioscler Thromb Vasc Biol. 2006;26:1144-1149.
46. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Van-haecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261. (Pubitemid 350190755)
47. Gissi-HF I, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372: 1231-1239.